BWA
IOVA icon

Basecamp Wealth Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Basecamp Wealth Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.05K Buy
493
+343
+229% +$1.3K ﹤0.01% 1366
2026
Q1 		$527 Hold
150
– – ﹤0.01% 1712
2025
Q4 		$410 Buy
+150
New +$347 ﹤0.01% 1660

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Basecamp Wealth Advisors's IOVA Position: Q2 2026 in Review

Basecamp Wealth Advisors increased its Iovance Biotherapeutics (IOVA) stake by 229% in Q2 2026, buying an estimated $1.3K and bringing the position to 493 shares worth $2.05K. The position accounts for ﹤0.01% of the portfolio, ranked #1366.

Basecamp Wealth Advisors first reported a position in IOVA in Q4 2025 and has held it in 3 quarters since. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Basecamp Wealth Advisors held 493 shares of Iovance Biotherapeutics worth $2.05K as of Q2 2026.
  • Basecamp Wealth Advisors bought 343 Iovance Biotherapeutics shares in Q2 2026, an estimated $1.3K.
  • Iovance Biotherapeutics made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1366 holding.
  • Basecamp Wealth Advisors first reported a position in Iovance Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.